Review



test sequence  (Psychology Software Tools)


Bioz Verified Symbol Psychology Software Tools is a verified supplier
Bioz Manufacturer Symbol Psychology Software Tools manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    Psychology Software Tools test sequence
    Test Sequence, supplied by Psychology Software Tools, used in various techniques. Bioz Stars score: 99/100, based on 39936 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/E-Prime/pmc12928708-80-12-19
    Average 99 stars, based on 39936 article reviews
    test sequence - by Bioz Stars, 2026-10
    99/100 stars

    Images

    Related Articles

    Sequencing:

    Article Title: Cortical inhibition and activation during sensorimotor tasks in an aquatic environment: a pilot EEG study based on expert-novice paradigm
    Article Snippet: .. The total flexion and extension task was 100 s, with the entire test sequence controlled by E-prime 3.0 (3.0.3.80, Psychology Software Tools, Sharpsburg, PA). .. EEG signals were recorded utilizing a 64-channel EEG system (Neuroscan, Germany) and digitized at a sampling rate of 1,000 Hz, adhering to the standardized international 10-10 electrode placement protocol.



    Similar Products

    99
    Psychology Software Tools test sequence
    Test Sequence, supplied by Psychology Software Tools, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/E-Prime/pmc12928708-80-12-19
    Average 99 stars, based on 1 article reviews
    test sequence - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    86
    Karius Inc karius test sequencing
    Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
    Karius Test Sequencing, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/karius+spectrum/pmc12968814-148-15-15
    Average 86 stars, based on 1 article reviews
    karius test sequencing - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Karius Inc metagenomic sequencing based test
    Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
    Metagenomic Sequencing Based Test, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12955461-11-71-74
    Average 86 stars, based on 1 article reviews
    metagenomic sequencing based test - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    97
    Foundation Medicine Inc next generation sequencing tests
    Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
    Next Generation Sequencing Tests, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/FoundationOne+Liquid+CDx/pm41686740-588-10-8
    Average 97 stars, based on 1 article reviews
    next generation sequencing tests - by Bioz Stars, 2026-10
    97/100 stars
      Buy from Supplier

    86
    Minitab Inc test sequence
    Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
    Test Sequence, supplied by Minitab Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/sequence+test/10__1016_slash_j__wds__2026__100274-128-18-22
    Average 86 stars, based on 1 article reviews
    test sequence - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Quest Diagnostics notch3 cadasil sequencing test
    Summary of enrolled plasma <t>mcfDNA-sequencing</t> studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.
    Notch3 Cadasil Sequencing Test, supplied by Quest Diagnostics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/cadasil+notch3+sequencing+test/us12496296-503-12-10
    Average 86 stars, based on 1 article reviews
    notch3 cadasil sequencing test - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Karius Inc bal fluid mcfdna sequencing test report
    Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
    Bal Fluid Mcfdna Sequencing Test Report, supplied by Karius Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/mcfdna+sequencing/med_rxiv__2025__11__05__25339543-51-4-28
    Average 86 stars, based on 1 article reviews
    bal fluid mcfdna sequencing test report - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    86
    Invitae Inc next generation sequencing ngs diagnostic test
    Flow diagram depicting patient and sample selection for the comparison of <t>BAL</t> fluid <t>mcfDNA</t> <t>sequencing</t> with the Karius® test and standard of care testing.
    Next Generation Sequencing Ngs Diagnostic Test, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/test+sequence/generation+next+sequencing/pmc12659938-53-10-15
    Average 86 stars, based on 1 article reviews
    next generation sequencing ngs diagnostic test - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    Image Search Results


    Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

    Journal: Infection and Drug Resistance

    Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

    doi: 10.2147/IDR.S562107

    Figure Lengend Snippet: Summary of enrolled plasma mcfDNA-sequencing studies published from 1st January 2015 to 28th February 2025. USA*: Refer to. , , , , China*: Refer to. , Germany*:Refer to.

    Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

    Techniques: Clinical Proteomics, Sequencing

    The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

    Journal: Infection and Drug Resistance

    Article Title: Refining the Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing in High-Risk Population of Infection: A Narrative Review

    doi: 10.2147/IDR.S562107

    Figure Lengend Snippet: The refinement strategy of clinical utility of plasma mcfDNA sequencing and prospective. *Co-mNGS Integration (Plasma + Blood Cell DNA): Cost-effectiveness should be further investigated, particularly in resource-limited settings.

    Article Snippet: Christians et al developed a workflow that enriches ultrashort and rare mcfDNA fragments prior to Karius test sequencing, enabling the identification of key AMR genes, such as SCCmec, mecA, mecC, vanA, vanB, blaCTX-M , and blaKPC , with diagnostic yields ranging from 56.8% to 83.3%.

    Techniques: Clinical Proteomics, Sequencing

    Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

    Journal: medRxiv

    Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

    doi: 10.1101/2025.11.05.25339543

    Figure Lengend Snippet: Flow diagram depicting patient and sample selection for the comparison of BAL fluid mcfDNA sequencing with the Karius® test and standard of care testing.

    Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

    Techniques: Selection, Comparison, Sequencing

    Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

    Journal: medRxiv

    Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

    doi: 10.1101/2025.11.05.25339543

    Figure Lengend Snippet: Additive diagnostic value of BAL fluid mcfDNA sequencing with the Karius® test (KT-BAL) compared to standard of care (SOC) testing in immunocompromised patients with pneumonia. A) Number of organisms across all samples identified by either SOC alone, KT-BAL alone, or both techniques, split by KT-BAL category. B) Organisms identified exclusively by KT-BAL across all samples, split by KT-BAL category.

    Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

    Techniques: Diagnostic Assay, Sequencing

    Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

    Journal: medRxiv

    Article Title: Microbial cell-free DNA sequencing of bronchoalveolar lavage fluid improves diagnostic yield and may add clinical utility in immunocompromised patients with severe pneumonia

    doi: 10.1101/2025.11.05.25339543

    Figure Lengend Snippet: Patients for whom BAL fluid mcfDNA testing with the Karius® test (KT-BAL) identified Category One or Two organisms missed by standard of care (SOC) had significantly more cumulative intubation days compared to patients where KT-BAL and SOC were concordant for all Category One or Two organisms. Hospital length of stay, ICU length of stay, and ICU mortality were worse in the KT-BAL only group, but these differences were not significant (Mann-Whitney U test for continuous variables, Fisher’s exact test for mortality).

    Article Snippet: For each sample, the BAL fluid mcfDNA sequencing test report included the name of each identified organism, the number of microbial reads found for the organism, and the Karius® designation for the pathogenicity of the organism (see Definitions).

    Techniques: MANN-WHITNEY